HRTX — HERON THERAPEUTICS, INC. /DE/

—
Nasdaq · Health Care · Pharmaceuticals · CIK 818033 ·
Last close
$0.28
Market Cap
$53.70M
52W High
$1.58
52W Low
$0.26
ADV30
7,165,658
Next earnings
2026-11-09
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 35,250,000 26,292,000 -1,669,000 -5,006,000 230,448,000 11,595,000 225,532,000
Jun 2026 37,666,000 26,094,000 -2,044,000 -5,489,000 252,262,000 20,721,000 245,354,000
Mar 2026 34,711,000 24,073,000 -4,765,000 -8,111,000 246,216,000 26,117,000 237,079,000
Dec 2025 40,588,000 29,469,000 38,000 -2,954,000 255,877,000 28,647,000 241,544,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-13,731,000
Investing CF
$434,000
Financing CF
$-18,176,000
CapEx
$-839,000
Dividends Paid
—
Buybacks
$-51,000
EPS Diluted TTM
$-0.12
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,953,389,000
Inventory
$90,585,000
Receivables
$89,571,000
ST Investments
$21,943,000
EBIT TTM
$-18,916,000
Pretax Income TTM
$-34,049,000
Interest Exp TTM
—
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$148,215,008
EBITDA
$-6,531,000
Free Cash Flow
$-12,147,625
Enterprise Value
$168,409,952
Total Cash
$23,449,000
Total Debt
$131,729,000
Shares Out
190,273,587
Trailing EPS
$-0.11
Book Value
$0.02
ROE
-217.8%
ROA
-2.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 154,904,000 -2,538,000 -20,195,000 255,877,000 241,544,000 14,333,000 -27,591,000
Dec 2024 144,285,000 -11,528,000 -13,580,000 233,147,000 266,798,000 -33,651,000 -22,529,000
Dec 2023 127,044,000 -110,615,000 -110,559,000 222,506,000 256,479,000 -33,973,000 -58,789,000
Dec 2022 107,672,000 -174,658,000 -182,024,000 250,951,000 237,379,000 13,572,000 -146,912,000

TTM Snapshot

Revenues TTM
$151,178,000
NetIncome TTM
$-34,049,000
OpCashFlow TTM
—
Assets (Latest)
$252,262,000
Forward EPS
$-0.12

Max Pain — expiry 2026-12-18

max pain strike: $0.50 · spot: $0.27 · call oi: 3,439 · put oi: 119
Expected Move to 2026-12-18: ±$0.26 (96.30%) — implied range $0.01 – $0.53 · ATM straddle on $0.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VRCA Verrica Pharmaceuticals Inc. $53.94M $3.14 —
IBO IMPACT BIOMEDICAL INC. $53.31M $6.17 —
XLO Xilio Therapeutics, Inc. $53.26M $7.54 —
INCR Intercure Ltd. $54.16M $3.61 —
XBIT XBiotech Inc. $54.27M $1.78 —

News headlines (Yahoo Finance, 1h cache)

CorMedix Inc. Q3 2026 Earnings Call Summary
2026-11-12 18:03 · Yahoo
Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 12:30 · Yahoo
CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings
2026-11-10 11:12 · Yahoo
Heron Therapeutics Reports 7.8% Decline in Q3 Revenue to $35.3 Million and Announces Proposed Asset Sale
2026-11-09 15:43 · Yahoo
CorMedix stock gains as Heron deal adds four products
2026-11-09 13:59 · Yahoo
Heron Therapeutics Announces Third Quarter 2026 Financial Results
2026-11-09 13:30 · Yahoo
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
2026-11-09 13:25 · Yahoo
Heron Therapeutics: Q3 Earnings Snapshot
2026-11-09 13:23 · Yahoo
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
2026-11-09 12:15 · Yahoo
Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
2026-10-27 00:09 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.